ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NVTR Nuvectra Corporation

0.13
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nuvectra Corporation NASDAQ:NVTR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.13 0.1304 0.15 0 01:00:00

Nuvectra to Present at the 29th Annual Piper Jaffray Healthcare Conference

15/11/2017 9:01pm

GlobeNewswire Inc.


Nuvectra (NASDAQ:NVTR)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Nuvectra Charts.

Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference.

   Event:29th Annual Piper Jaffray Healthcare Conference
 Date:Tuesday, November 28, 2017
 Time:4:30 p.m. ET
 Location:Lotte NY Palace Hotel, New York

A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the chat will be available for 90 days.

About Nuvectra Corporation

NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.

Company Contacts:            Nuvectra Corporation         Walter Berger, COO & CFO (214) 474-3102                      wberger@nuvectramed.com              

Investor Contacts:The Ruth Group                  Zack Kubow / Brian Johnston(646) 536-7020 / 7028           investors@nuvectramed.com

 

 

1 Year Nuvectra Chart

1 Year Nuvectra Chart

1 Month Nuvectra Chart

1 Month Nuvectra Chart

Your Recent History

Delayed Upgrade Clock